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Previous literature suggests that Alzheimer’s disease (AD) process may contribute to
late-life onset depression (LLOD). Therefore, we investigated the association of LLOD
with cerebral amyloidosis and neuronal injury, the two key brain changes in AD, along
with vascular risks. Twenty nine non-demented individuals who first experienced major
depressive disorder (MDD) after age of 60 years were included as LLOD subjects, and 27
non-demented elderly individuals without lifetime experience of MDD were included as
normal controls (NC). Comorbid mild cognitive impairment (MCI) was diagnosed in 48%
of LLOD subjects and in 0% of NC. LLOD, irrespective of comorbid MCI diagnosis, was
associated with prominent prefrontal cortical atrophy. Compared to NC, LLOD subjects
with comorbid MCI (LLOD 11MCI) showed increased cerebral C-Pittsburg compound
B (PiB) retention and plasma beta-amyloid 1–40 and 1–42 peptides, as measures of
cerebral amyloidosis; and, such relationship was not observed in overall LLOD or LLOD
without MCI (LLODwoMCI). LLOD subjects, particularly the LLODwoMCI, had higher systolic
blood pressure (SBP) than NC. When analyzed in the same multiple logistic regression
model that included prefrontal gray matter (GM) density, cerebral amyloidosis, and SBP
as independent variables, only prefrontal GM density showed a significant independent
association with LLOD regardless of MCI comorbidity status. Our findings suggest
AD process might be related to LLOD via prefrontal neuronal injury in the MCI stage,
whereas vascular processes—SBP elevation, in particular—are associated with LLOD
via prefrontal neuronal injury even in cognitively intact or less impaired individuals.
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INTRODUCTION
Late-life onset depression (LLOD), most commonly defined as
depression occurring for the first time at the age of 60 years or
older, has distinct clinical characteristics such as high medical
comorbidity compared to early-life onset depression (ELOD;
Salloway et al., 1996; Potter and Steffens, 2007). In addition,
since cerebrovascular changes and vascular risk factors (VRFs)
are more commonly observed in LLOD than ELOD subjects,
the “vascular depression” hypothesis has been proposed as a
possible biological etiology of LLOD (Alexopoulos et al., 1997a,b;
Krishnan et al., 1997).
However, previous studies suggested that neurodegenerative
processes, Alzheimer’s disease (AD) in particular, may contribute
to LLOD, which might be an early prodromal symptom of AD
(Brommelhoff et al., 2009; Panza et al., 2010). According to
prior epidemiological studies, the prevalence rates of depressive
symptoms increased within 3 years preceding the diagnosis of
AD dementia and were significantly higher in subjects with
mild cognitive impairment (MCI) than normal controls (NC;
Berger et al., 1999; Lopez et al., 2003). Such findings indicate
that AD-related pathological processes, such as beta-amyloid
(Aβ) deposition and related neuronal injury, might contribute
to the occurrence of LLOD by increasing brain vulnerability
(Weisenbach and Kumar, 2014).
In line with epidemiological findings, some studies reported
altered plasma levels of Aβ peptides or their ratio, considered
potential biomarkers for increased risk of AD or MCI (Song
et al., 2011), in elderly individuals with depression (Pomara
et al., 2006; Qiu et al., 2007), and proposed the term “amyloid-
associated depression” as a prodromal manifestation of AD
(Sun et al., 2008). However, since plasma Aβ biomarkers are
indirect measures for probing cerebral amyloid burden and
direction of change was inconsistent among previous studies,
direct quantification of Aβ deposition in in vivo human brain
is required to accurately assess the state of cerebral amyloidosis
in LLOD subjects. Recently, several studies compared cerebral
amyloid burden between subjects with late-life depression and
NC using amyloid positron emission tomography (PET) imaging
with 11C-Pittsburg compound B (PiB) or 18F-Florbetapir tracer
(Butters et al., 2008a; Madsen et al., 2012; Wu et al., 2014).
However, all these studies, which showed conflicting results,
defined depression as a “late-life depression” (Butters et al.,
2008a) or “lifetime history of major depression in the elderly”
(Madsen et al., 2012; Wu et al., 2014); these definitions
incorporate not only LLOD but also ELOD that recurs or
continues in the late-life period (Panza et al., 2010). To date,
whether cerebral amyloidosis is associated with pure LLOD and
plays a critical role in the development of LLOD remains unclear.
Based onmagnetic resonance imaging (MRI) studies, LLOD is
closely associated with structural brain changes such as regional
cortical atrophy, a marker for neuronal injury (Bobinski et al.,
2000; Frisoni et al., 2010; Hampel et al., 2010; Jack et al.,
2010, 2011; Vemuri and Jack, 2010; Whitwell and Vemuri,
2011), especially in prefrontal regions (Kumar et al., 1998;
Almeida et al., 2003). Although the vascular process has been
suggested as their cause (Alexopoulos et al., 1997a), structural
brain changes in LLOD may be due to the neuronal injury
associated with the pathological process of AD, which is initiated
by cerebral Aβ deposition (Jack et al., 2010; Sperling et al., 2011).
Thus, to clearly elucidate the integrative amyloid-associated
neurobiological process that underlies LLOD, neuronal injury
process identified by MRI-measured atrophy, as well as cerebral
amyloid burden, should also be examined simultaneously along
with the vascular risks. Nevertheless, to date, no studies have
investigated cerebral amyloid burden and regional cortical
atrophy in LLOD individuals by integrating the perspectives of
AD and the vascular process.
Elucidating the underlying pathophysiology of LLOD,
particularly its association with neurodegenerative process such
as cerebral amyloidosis and neuronal injury in non-demented
elderly individuals will provide us insight on predicting the
prognosis of and developing the novel therapeutic approaches
for LLOD in clinical practice (Pomara and Sidtis, 2007;
Mahgoub and Alexopoulos, 2016). In the present study, we
aimed to investigate whether LLOD is associated with cerebral
amyloidosis and regional neuronal injury, along with the vascular
risks, in elderly individuals with no dementia. We first examined
regional cortical atrophy using voxel-by-voxel analysis to identify
regional neuronal injury related to LLOD. Next, we investigated
the association of LLOD with cerebral amyloidosis, as measured
by both cerebral Aβ deposition and plasma Aβ peptides levels,
and vascular risks. Finally, we investigated whether regional
neuronal injury, cerebral amyloidosis or vascular risks were
independently associated with a diagnosis of LLOD. Because a
diagnosis of MCI is considered to be associated with increased
cerebral amyloidosis (Wolk et al., 2009), the vascular process
(Casado Naranjo et al., 2015), and cortical atrophy (Jack et al.,
2010), we also explored whether the association of LLOD with
cerebral amyloidosis, vascular process, or regional cortical
atrophy differs according to the presence of MCI.
MATERIALS AND METHODS
Participants
Elderly individuals who first experienced a major depressive
disorder (MDD), as defined by the Diagnostic and Statistical
Manual of Mental Disorders, 4th Edition (DSM-IV; First et al.,
1996), after the age of 60 years were recruited from the Geriatric
Psychiatry Clinic of the Seoul National University Hospital
(SNUH) as LLOD subjects. In addition, elderly individuals
without lifetime experience of MDD were recruited from
the community as NC. To diagnose and characterize onset
and course of MDD, as well as to exclude other psychiatric
disorders, all participants underwent a standardized interview
including the Structured Clinical Interview for DSM-IV (SCID)
that is required for the diagnosis of MDD by board-certified
psychiatrists at the time of recruitment. Reliable informants
were also interviewed and medical records were reviewed
for more accurate information. Exclusion criteria for both
groups were: (1) dementia according to DSM-IV criteria; (2)
comorbid major neuropsychiatric illnesses other than MDD;
(3) a history of significant systemic illness/neurologic disorder;
(4) major abnormal findings on brain MRI; (5) a history of
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electroconvulsive therapy; or, (6) contraindications for the MRI
scan. The presence of MCI was not included in the exclusion
criteria for both groups. Among the initially recruited 59
subjects, 3 LLOD participants were excluded from the final
analysis due to significant abnormalities on MRI (i.e., acute
infarct, old hemorrhage, and severe brain parenchymal tissue
loss). The study was approved by the Institutional Review
Board of SNUH and all participants provided written informed
consent. This study was conducted in accordance with the
recommendations of the current version of the Declaration of
Helsinki.
Clinical and Neuropsychological
Assessment
Although all LLOD subjects were in MDD state at the time
of enrollment, most of them (90%) were remitted from MDD
after receiving treatment in the clinic at the time of the
detailed examination including neuropsychological tests and
MRI/PET scan. Severity of depressive symptoms at the time
of the examination was measured using the 17-item Hamilton
Rating Scale for Depression (Mulsant et al., 1994), the 30-item
Korean version of the Geriatric Depression Scale (GDS; Yesavage
et al., 1982; Bae and Cho, 2004) and Montgomery-Åsberg
Depression Rating Scale (Montgomery and Asberg, 1979). All
subjects received standardized clinical and neuropsychological
assessments according to the protocol of the Korean version of
the Consortium to Establish a Registry for Alzheimer Disease
(CERAD)Assessment Packet (Morris et al., 1989; Lee et al., 2002),
the CERAD neuropsychological battery (Lee et al., 2004) and
the Stroop test (Seo et al., 2008) by board-certified psychiatrists
and neuropsychologists. MCI was diagnosed according to the
international consensus criteria (Winblad et al., 2004) and
detailed information on the diagnostic criteria for MCI used in
this study is described in elsewhere (see Supplementary Text).
The presence or absence of six VRFs, including hypertension,
diabetes, dyslipidemia, heart disease, transient ischemic attack,
and stroke was systematically assessed for each participant; the
participant’s history was provided by an informant and the
medical records were reviewed. As a composite score of VRFs,
the VRF score (VRS) was calculated as the number of the VRFs
present and reported as a percentage (DeCarli et al., 2004). The
systolic/diastolic blood pressure (SBP/DBP) was measured at
supine position by trained nurse using sphygmomanometer and
body mass index (BMI) were also assessed.
MRI Acquisition, Pre-processing, and
Analyses
MRI scanning was performed using a 3T Siemens TrioTim
magnetic resonance scanner (Siemens AG, Erlangen, Germany)
to acquire three-dimensional (3-D) T1-weighted magnetization-
prepared rapid gradient-echo (MPRAGE) and fluid-attenuated
inversion recovery (FLAIR) sequences. Detailed information on
MRI sequences and parameters is described in elsewhere (see
Supplementary Text).
Voxel-based morphometry (VBM) analysis was performed
using Statistical Parametric Mapping 8 (SPM8, Wellcome
Department of Cognitive Neurology, London, UK; http://www.
fil.ion.ucl.ac.uk/spm/) with the VBM8 toolbox (http://dbm.
neuro.uni-jena.de/vbm/) to demonstrate group differences in
regional gray matter (GM) density between the NC and LLOD
groups. All T1-weighted images of each subject were normalized
into standard anatomical space using MNI 152 template with
a linear 12-parameter affine transformation. Next, normalized
images were segmented into GM, white matter and cerebrospinal
fluid. Smoothing at 12-mm full width at half maximum was
performed after segmentation and modulation.
For the rating of white matter hyperintensity (WMH), all
MRIs with FLAIR sequence were assessed blinded to clinical
information by one experienced rater according to the Fazekas
scale (Fazekas et al., 1987), where the severity of periventricular
and deep WMH was scaled on a 0 (absence) to 3 (severe)
separately.
11C-PiB PET Image Acquisition,
Pre-processing, and Analyses
Participants also underwent 11C-PiB PET imaging using
Biograph PET/CT scanners (Siemens, TN, USA). All participants
underwent 11C-PiB PET imaging using Biograph PET/CT
scanners (Siemens, TN, USA). For each subject, 550–750
MBq of 11C-PiB was administered by intravenous injection.
A 20 min emission scan was obtained in 3D mode starting
50 min after injection and a CT scan was performed for
attenuation correction (120 kVp, 40 mAs, pitches of 0.8). PET
reconstructions were performed using a point spread function-
based iterative algorithm (TrueX; 6 iterations, 21 subsets) with a
matrix 256 × 256 in size (74 slices, voxel size: 1.3364 × 1.3364
mm2; slice thickness: 3 mm), and reconstructed images were
rearranged onto transaxial, sagittal and coronal images.
Image preprocessing for statistical analyses was performed
using SPM8 implemented in Matlab (MathWorks, Natick, MA,
USA). The 11C-PiB PET data of each subject were co-registered
to individual volumetric magnetic resonance images and then
automatically spatially normalized into the standard MNI
template in SPM8 using transformation parameters derived from
the normalization of individual MRI scans to the template. All
normalized images were reformatted with a 2 × 2 × 2 mm
voxel. For quantitative normalization of cerebral 11C-PiB uptake
values, the cerebellum was used as a reference region (Lopresti
et al., 2005) and 11C-PiB retention maps, as region-to-cerebellar
ratios, were generated by dividing regional uptake values by the
individual mean cerebellar uptake values in the same images.
The automatic anatomic labeling algorithm (Tzourio-
Mazoyer et al., 2002) and a region combining method (Reiman
et al., 2009) were applied to set regions-of-interest (ROIs) to
characterize 11C-PiB retention level in frontal, lateral parietal,
posterior cingulate-precuneus (PC-PRC), lateral temporal and
basal ganglia (BG) regions. Mean cortical amyloid burden was
calculated for a global PiB retention index by averaging the mean
ROI value except BG. The image was classified as PiB-positive if
the standardized uptake value ratio (SUVR) of 11C-PiB retention
was 1.4 or higher in one of the following cortical ROIs: frontal,
lateral temporal, lateral parietal, or PC-PRC (Choe et al., 2014).
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Plasma Aβ Peptide Level Assessment and
Apolipoprotein E (APOE) Genotyping
Fasting blood samples were collected in the morning by
venipuncture in tubes containing EDTA as anticoagulant.
After centrifugation, plasma samples were aliquoted into
polypropylene tubes and stored at −80◦C pending biochemical
analyses without being thawed and refrozen. Quantification of
plasma Aβ isoforms was performed using INNO-BIA plasma Aβ
forms assays (Innogenetics, Ghent, Belgium) and the Bio-Plex
200 system with high throughput fluidics (BIO-RAD, Hercules,
CA, USA) based on a previous study (Hansson et al., 2010).
Genomic DNA was extracted from venous blood and APOE
genotyping was performed according to the method described
previously (Wenham et al., 1991).
Statistical Analyses
For comparison of demographic and clinical variables between
the two groups, independent t-test for continuous variables and
chi-square or Fisher’s exact test for categorical variables was
used (p < 0.05, two-sided). Neuropsychological variables were
compared between the two groups using analysis of covariance
(ANCOVA) with age, gender, educational level and GDS score
as covariates. VBM analysis was performed to identify the
region where LLOD subjects showed greater cortical atrophy
compared with NC at both uncorrected p < 0.001 (k = 100)
and family-wise error (FWE)-corrected p < 0.05 (k = 100), after
controlling for age, gender and educational level. Comparison
of PiB retention level, as well as plasma Aβ peptide level,
between the two groups was performed using ANCOVA after
controlling for age, gender and educational level. Multiple logistic
regression analysis with diagnostic state (NC vs. LLOD) as a
dependent variable was performed to investigate the independent
association of regional neuronal injury, cerebral amyloidosis,
and vascular risk with occurrence of LLOD after controlling for
age, gender, and educational level. All of the abovementioned
analyses were performed again after excluding LLOD subjects
with MCI (LLODMCI) to characterize the LLOD subjects without
MCI (LLODwoMCI) and vice versa.
RESULTS
Demographic, Clinical, and
Neuropsychological Characteristics
Differences in terms of age, gender, and educational level, as
well as APOE ε4 carrier frequency, were not significant between
LLOD subjects and NC (Table 1). Although 26 out of 29 LLOD
patients were remitted from MDD at the time of examination,
LLOD patients had significantly higher scores on the depression
symptom scale than NC. In addition, 48% of LLOD subjects and
none of the NC were diagnosed with comorbid MCI.
In terms of vascular risk evaluation, no significant differences
in VRS, BMI, and DBP were observed between NC and LLOD
subjects. However, SBP was significantly higher in LLOD subjects
than in NC. In subgroup analysis, LLODwoMCI subjects had
significantly higher SBP than NC. Mean of SBP in LLODMCI
subjects was higher than that of NC group; but, it was not
statistically significant. Even among the subjects treated with
antihypertensives, SBP of LLOD group was still significantly
higher than NC. Additionally, mean of periventricular WMH
severity was higher in LLOD group compared to NC; but, it was
not statistically significant.
Compared with NC, LLOD subjects showed significantly
greater impairments on multiple cognitive tests including the
Mini-mental State Examination (MMSE), Semantic fluency,
Word-list memory and Constructional praxis of the CERAD
neuropsychological battery, and all Stroop tests (Supplementary
Table 1).
Regional Cortical Atrophy in LLOD
On VBM analysis, LLOD individuals demonstrated regional
cortical atrophy in the bilateral prefrontal regions including
the medial prefrontal areas as well as the bilateral parietal and
temporal regions compared with NC at uncorrected p < 0.001,
k= 100 (Figure 1A and Supplementary Table 2). After correction
for multiple comparisons (FWE-corrected p < 0.05, k = 100),
LLOD subjects still showed significant prefrontal atrophy mainly
in the right medial prefrontal region (Figure 1B). Prefrontal
cortical atrophy with peak voxel located in the right medial
prefrontal region (peak MNI: 11, 57, 9) was similarly observed
when LLODwoMCI and LLODMCI subjects were compared to NC
separately at uncorrected p < 0.001, k = 100 (Figures 1C,D and
Supplementary Table 3).
Cerebral PiB Retention and Plasma Aβ
Peptide Level in LLOD
Overall, LLOD patients showed no significant differences in both
global PiB retention and the PiB-positivity rate compared with
NC (Table 2 and Figure 2). Regional PiB retention in the frontal,
lateral parietal, PC-PRC, lateral temporal, or BG regions was also
not significantly different between NC and LLOD subjects. In
terms of plasma Aβ peptides level, no significant differences were
observed in all plasma Aβ peptide measurements or their ratios
between NC and LLOD subjects (Table 3).
In subgroup analysis, LLODwoMCI subjects did not show
significant differences in global or regional PiB retention levels,
or in the PiB-positivity rate compared with NC. Similarly, plasma
Aβ peptides levels were not different between LLODwoMCI
subjects and NC. However, LLODMCI subjects had significantly
more PiB-positive cases and showed higher global and regional
PiB retention than NC (Table 2 and Figure 2). In addition,
plasma Aβ1–42 and Aβ1–40 peptide levels were significantly
higher in LLODMCI subjects than NC (Table 3).
Independent Association of Regional
Neuronal Injury, Cerebral Amyloidosis, and
Vascular Process with LLOD Diagnosis
Multiple logistic regression analysis with diagnostic state (NC vs.
LLOD) as a dependent variable was performed to investigate the
independent relationship of regional neuronal injury, cerebral
amyloidosis, and vascular risk with LLOD diagnosis. For this
analysis, regional neuronal injury was defined as mean GM
density extracted from a prefrontal ROI that was set as a
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TABLE 1 | Demographic and clinical characteristics of the subjects.
NC (N = 27) LLOD (N = 29) LLODwoMCI (N = 15) LLODMCI (N = 14)
DEMOGRAHPIC CHARACTERISTICS
Age (years) 68.70 ± 6.06 71.62 ± 5.08 71.40 ± 5.11 71.86 ± 5.23
Gender (M/F) 14/13 8/21 6/9 2/12*
Educational level (years) 10.81 ± 4.52 8.69 ± 4.54 9.93 ± 4.94 7.36 ± 3.80*
APOE ε4 carrier/non-carrier 5/22 3/26 0/15 3/11
CLINICAL CHARACTERISTICS
Age at onset of first MDD (years) – 68.12 ± 4.49 67.27 ± 4.47 69.04 ± 4.50
Duration since first MDD onset (years) – 3.50 ± 3.13 4.13 ± 3.44 2.82 ± 2.71
GDS 5.85 ± 3.96 12.00 ± 5.76** 12.00 ± 5.96** 12.00 ± 5.75**
HRSD 1.22 ± 1.67 4.66 ± 3.95** 4.61 ± 3.20* 4.71 ± 4.75*
MADRS 1.70 ± 2.05 6.79 ± 5.57** 5.87 ± 2.97** 8.14 ± 7.38*
Subtype of MCI (aMCI/naMCI) – – – 6/8
VASCULAR RISKS EVALUATION
VRS (%) 19.75 (15.36) 16.67 (14.77) 17.78 (14.73) 15.48 (15.28)
BMI (kg/m2) 24.85 ± 2.92 23.45 ± 3.16 23.34 ± 3.72 23.57 ± 2.57
SBP (mmHg) 118.81 ± 9.82 126.52 ± 13.23* 127.60 ± 14.75* 125.36 ± 11.82a
DBP (mmHg) 79.56 ± 7.53 78.14 ± 8.56 78.73 ± 8.98 77.50 ± 8.37
Use of antihypertensives, N (%) 15 (55.6) 13 (44.8) 8 (53.3) 5 (35.7)
SBP_under antihypertensivesb 119.20 ± 10.47 128.23 ± 10.67* 129.63 ± 13.21 126.00 ± 5.15
DBP_under antihypertensivesb 78.13 ± 8.50 77.31 ± 7.32 79.25 ± 7.17 74.20 ± 7.16
Periventricular WMH 0.96 ± 0.76 1.31 ± 0.60c 1.27 ± 0.59 1.36 ± 0.63
Deep WMH 1.26 ± 0.45 1.31 ± 0.47 1.33 ± 0.49 1.29 ± 0.47
Data are presented as mean ± SD or numbers.
*Significant difference compared to NC (p < 0.05).
**Significant difference compared to NC (p < 0.001).
aSBP of LLODMCI was higher than NC but did not reach statistical significance (p = 0.067).
bData are presented as mean ± SD among subjects who took antihypertensives.
cMean of periventricular WMH severity was higher in LLOD group compared to NC; but, it was not statistically significant (p = 0.062).
NC, Normal Controls; LLOD, Late-life Onset Depression; MCI, Mild Cognitive Impairment; LLODwoMCI, LLOD without MCI; LLODMCI, LLOD with MCI; APOE, Apolipoprotein E; MDD,
Major Depressive Disorder; GDS, The Korean version of the Geriatric Depression Scale; HRSD, Hamilton Rating Scale of Depression; MADRS, Montgomery-Åsberg Depression Rating
Scale; aMCI, amnestic MCI; naMCI, non-amnestic MCI; VRS, Vascular Risk Factor Score; BMI, Body Mass Index; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; WMH,
White Matter Hyperintensity.
cluster where LLOD subjects showed reduced GM density at
FWE-corrected p < 0.05 (peak MNI: 11, 57, 9; T = 5.79;
463 voxels). In addition to prefrontal ROI GM density, global
PiB retention, as a measure of cerebral amyloidosis, and SBP,
a vascular risk that was significantly different between NC
and LLOD subjects, were included in the regression model
as independent variables. After adjusting for age, gender and
educational level, only prefrontal ROI GM density showed a
significant association with LLOD diagnosis [odds ratio (OR) =
0.47 per 0.01; 95% confidence interval (CI): 0.29 – 0.75], whereas
global PiB retention (OR = 1.07 per 0.01 SUVR; 95% CI: 0.99 –
1.15) and SBP (OR= 1.06 per 1 mmHg; 95% CI: 0.99 – 1.14) did
not in the samemodel. Moreover, prefrontal ROIGMdensity was
significantly associated with LLODwoMCI diagnosis (OR = 0.25
per 0.01; 95% CI 0.07 – 0.85) or LLODMCI diagnosis (OR = 0.56
per 0.01; 95% CI 0.36 – 0.86) in the regression models, but global
PiB retention and SBP were not.
DISCUSSION
We found that nearly half of the subjects who experienced LLOD
had comorbid cognitive impairment compatible with MCI,
which was not observed in NC. LLOD, irrespective of comorbid
MCI diagnosis, was associated with prominent prefrontal cortical
atrophy. The LLODMCI subgroup showed increased cerebral
PiB retention and plasma Aβ peptide levels as measures of
cerebral amyloidosis, compared with NC, while overall LLOD
and LLODwoMCI subjects did not. In terms of the vascular
process, LLOD individuals had higher SBP than NC, particularly
when MCI did not coexist. When simultaneously analyzed in the
samemodel, only prefrontal cortical atrophy showed a significant
independent association with LLOD diagnosis, irrespective of
MCI status, while cerebral PiB retention and SBP did not. To
the best of our knowledge, this study is the first to investigate
both in vivo cerebral amyloidosis and regional cortical atrophy
simultaneously with vascular risks in the context of LLOD
occurrence.
As the accumulation of brain Aβ protein begins 15–20 years
before the onset of dementia in AD (Sperling et al., 2011), we
aimed to investigate whether LLOD is a secondary result of brain
Aβ deposition in the prodromal period of AD dementia. Thus, we
strictly recruited only elderly subjects with late-life onset major
depression, excluding ELOD cases to increase the homogeneity
of study participants. Reportedly, ELOD is a risk factor for
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FIGURE 1 | Regional GM atrophy of LLOD subjects compared to NC after controlling age, gender, and educational level (A) at uncorrected p < 0.001
(k = 100) and (B) FWE-corrected p < 0.05 (k = 100). (C) and (D) demonstrated regional GM atrophy in subjects with (C) LLODwoMCI and (D) LLODMCI at
uncorrected p < 0.001 (k = 100). NC, Normal Controls; LLOD, Late-life Onset Depression; MCI, Mild Cognitive Impairment; LLODwoMCI, LLOD without MCI;
LLODMCI, LLOD with MCI; GM, Gray Matter; FWE, Family-wise Error.
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TABLE 2 | Cerebral PiB retention level of subjects.
NC (N = 27) LLOD (N = 29) LLODwoMCI (N = 15) LLODMCI (N = 14)
REGIONAL PiB RETENTION
Frontal region 1.20 ± 0.15 1.31 ± 0.34 1.21 ± 0.18 1.42 ± 0.44*a
Lateral parietal region 1.08 ± 0.15 1.20 ± 0.32 1.14 ± 0.26 1.27 ± 0.38*a
PC-PRC region 1.23 ± 0.18 1.36 ± 0.36 1.28 ± 0.29 1.45 ± 0.42*a
Lateral temporal region 1.15 ± 0.11 1.26 ± 0.30 1.21 ± 0.17 1.33 ± 0.39b
BG 1.32 ± 0.14 1.38 ± 0.24 1.35 ± 0.15 1.43 ± 0.31
GLOBAL PiB RETENTION
Mean cortical PiB retention 1.18 ± 0.14 1.29 ± 0.32 1.21 ± 0.19 1.38 ± 0.41*a
PiB-positivity (%) 3 (11.1) 8 (27.6) 2 (13.3) 6 (42.9)*c
Data are presented as mean± SD or number (%). Regional and global PiB retention levels are shown as a standardized uptake value ratio (SUVR). For comparison of continuous variables,
analysis of covariance test was used with age, gender, and educational level as covariates and chi-square test or Fisher’s exact test was used for the comparison of categorical variable.
*Significant difference compared to NC (p < 0.05).
aLLODMCI subjects showed significantly higher PiB SUVR in frontal (p = 0.040), lateral parietal (p = 0.027), PC-PRC (p = 0.031) and mean cortical (p = 0.036) regions compared to
NC after controlling the effect of age, gender, and educational level.
bLLODMCI subjects had higher PiB SUVR in the lateral temporal region at marginal significance after controlling the effect of age, gender, and educational level (p = 0.051).
cPiB-positivity rate was significantly higher in LLODMCI subjectscompared to NC (p = 0.042, Fisher’s exact test).
PiB, Pittsburgh Compound B; NC, Normal Controls; LLOD, Late-life Onset Depression; MCI, Mild Cognitive Impairment; LLODwoMCI, LLOD without MCI; LLODMCI, LLOD with MCI;
PC-PRC, Posterior Cingulate-Precuneus; BG, Basal Ganglia; SUVR, Standardized Uptake Value Ratio.
TABLE 3 | Plasma Aβ peptides level of subjects.
NC (N = 27) LLOD (N = 29) LLODwoMCI (N = 15) LLODMCI (N = 14)
Plasma Aβ1–42 39.58 ± 7.82 43.51 ± 11.19 43.22 ± 10.71 43.81 ± 12.08*
a
Plasma Aβ1–40 176.03 ± 17.83 189.74 ± 35.68 179.54 ± 35.05 200.67 ± 34.21*
a
Plasma AβN–42 27.95 ± 6.05 30.56 ± 9.29 30.86 ± 8.49 30.24 ± 10.40
Plasma AβN–40 186.81 ± 22.54 195.19 ± 39.34 200.85 ± 45.49 189.12 ± 32.08
Aβ1–40/Aβ1–42 4.61 ± 1.03 4.60 ± 1.32 4.35 ± 1.14 4.87 ± 1.47
AβN–40/AβN–42 7.05 ± 2.13 7.13 ± 3.44 7.07 ± 2.82 7.21 ± 4.12
Data are presented as mean ± SD. Plasma Aβ peptide levels are shown as ng/L.
*Significant difference compared to NC (p < 0.05).
aLLODMCI subjects had significantly higher plasma Aβ1–42 and plasma Aβ1–40 peptides level compared to NC (p = 0.03 and p = 0.006, respectively) after controlling the effect of age,
gender and educational level.
NC, Normal Controls; LLOD, Late-life Onset Depression; MCI, Mild Cognitive Impairment; LLODwoMCI, LLOD without MCI; Aβ, Beta-amyloid.
developing AD dementia rather than a prodromal phenomenon
of AD dementia (Ownby et al., 2006; Byers and Yaffe, 2011).
Recent reports on changes in the serum or plasma Aβ1–40/Aβ1–42
ratio even in young-aged major depression patients (Baba et al.,
2012) or elderly subjects with ELOD (Pomara et al., 2006;
Namekawa et al., 2013) support the link between ELOD and
altered Aβ metabolism. Preclinical evidence also suggests that
stress responses related to depressive experiences contribute
to Aβ accumulation by initiating increased Aβ production
(Green et al., 2006; Kang et al., 2007) or interacting with
the amyloidogenic process linked to the serotonergic system
(Sierksma et al., 2010). Several previous studies have reported
elevated brain Aβ deposition or altered plasma Aβ biomarkers
in elderly depression (Qiu et al., 2007; Sun et al., 2008; Wu
et al., 2014). However, because these studies did not strictly define
elderly depression as LLOD, the findings were likely influenced
by an etiological contribution of earlier-onset depression to the
Aβ-related pathology such that comparison with our results is
difficult.
Although most LLOD subjects were in the remitted
state, approximately half had comorbid MCI, which was not
observed in NC. Considering that structural and functional
brain impairments are already prominent in the MCI state
(Pihlajamaki et al., 2009; Jack et al., 2010), the higher frequency
of comorbid MCI in LLOD subjects indicates that brain damage
or pathology is potentially more prevalent in this group, as
reported previously (Weisenbach and Kumar, 2014). Our study
also revealed prominent prefrontal cortical atrophy in LLOD
subjects, regardless of MCI diagnosis. The prefrontal region,
especially the medial prefrontal cortex, is important in emotional
processing (Elliott and Dolan, 2003). Structural abnormality in
the prefrontal region is a robust finding in previous structural
imaging studies on late-onset major depression (Kumar et al.,
1998) as well as overall MDD (Steele et al., 2007; Lorenzetti
et al., 2009). Reductions in neuronal cell size and density in the
prefrontal region in MDD were consistently found in previous
studies (Kim et al., 2016). Thus, our findings from structural
MRI analysis of the cerebral cortex, together with other prior
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FIGURE 2 | Mean cortical PiB retention level (SUVR) in subjects: (A) NC
vs. LLOD, (B) NC vs. LLODwoMCI,(C) NC vs. LLODMCI. *p < 0.05 (after
controlling the effect of age, gender, and educational level). PiB, Pittsburgh
Compound B; NC, Normal Controls; LLOD, Late-life Onset Depression; MCI,
Mild Cognitive Impairment; LLODwoMCI, LLOD without MCI; LLODMCI, LLOD
with MCI; SUVR, Standardized Uptake Value Ratio.
evidences, support that prefrontal neuronal injury is likely a
common neural substrate for the emergence of LLOD as well as
MDD in general, although underlying etiological factors could
be heterogeneous (Butters et al., 2008b; Weisenbach and Kumar,
2014).
While the regional neuronal injury was closely associated
with LLOD and did not differ according to the comorbid MCI
state, the relationship between cerebral amyloidosis and LLOD
depended on the presence of MCI. LLODMCI was closely related
with increased cerebral PiB retention and plasma Aβ1–42 and
Aβ1–40 peptide levels, whereas overall LLOD and LLODwoMCI
were not. These findings suggest that cerebral amyloidosis is not
the major determinant of LLOD in elderly individuals without
cognitive impairment compatible with MCI, but probably exerts
an influence on the occurrence of LLOD in subjects who are
in the MCI state. Our findings on the differential association of
cerebral amyloidosis and LLOD according to MCI comorbidity
might also explain inconsistencies among previous findings:
elderly subjects with current or history of depression showed
increased brain Aβ level when subjects had comorbid MCI
diagnosis, whereas those without MCI did not compared to NC
(Butters et al., 2008a;Wu et al., 2016). In addition, the proportion
of MCI comorbidity in study subjects as well as methodological
differences in plasma Aβ measurements might contribute to the
mixed results of previous studies on plasma Aβ level in elderly
individuals with depression (Pomara et al., 2006; Qiu et al., 2007;
Sun et al., 2008; Song et al., 2011; Baba et al., 2012; Namekawa
et al., 2013; Osorio et al., 2014).
We also found that SBP in LLOD patients was significantly
higher than in NC, particularly in LLODwoMCI subjects. LLOD
also tended to have higher WMH than NC. These results support
the previous vascular depression hypothesis (Alexopoulos et al.,
1997a) and indicate that the vascular process may have a greater
impact on the occurrence of LLOD in subjects who are not
in the MCI state and have a low probability of underlying
AD processes such as cerebral amyloidosis. Progressive cortical
thinning in the prefrontal region has also been reported in
hypertensive individuals (Gonzalez et al., 2015), suggesting that
the prefrontal cortical region is selectively susceptible to blood
pressure elevation.
When analyzed in the same multiple logistic regression
model that included prefrontal GM density, cerebral amyloidosis
and SBP as independent variables, only prefrontal GM density
showed a significant independent association with LLOD
diagnosis, regardless of MCI comorbidity state, which was not
observed for global PiB retention or SBP. These results indicate
that cerebral amyloidosis and elevated SBP only indirectly
contribute to LLOD occurrence via prefrontal neuronal injury.
The present study had several limitations. First, it used a
cross-sectional design and was limited in terms of providing
information on the causal contribution of cerebral amyloidosis or
blood pressure to LLOD. Second, the sample size for each LLOD
subgroup analysis, although conducted for exploratory purposes,
was relatively small, which might have reduced the statistical
power. Further studies with larger sample sizes and longitudinal
follow-ups are needed to address these issues.
In conclusion, our findings suggest that prefrontal neuronal
injury is probably a common brain alteration underlying the
occurrence of LLOD. Additionally, cerebral amyloidosis might
be associated with LLOD via prefrontal neuronal injury in the
MCI stage, in which structural and functional brain impairment
caused by the AD process begins to become prominent.
Meanwhile, the vascular process, SBP elevation in particular,
is associated with the occurrence of LLOD through prefrontal
neuronal injury even in cognitively intact or less impaired
individuals. From a clinical standpoint, an LLOD patient likely
has underlying AD pathologies in his/her brain, if the patient
is still in the MCI state even after the remission of depression.
However, this possibility is low if the patient is cognitively
less impaired and not in the MCI state after the remission of
Frontiers in Aging Neuroscience | www.frontiersin.org 8 October 2016 | Volume 8 | Article 236
Byun et al. Amyloidosis, Neuronal Injury in LLOD
depression. Instead, we should consider that vascular process is
a main contributor to LLOD in such cases.
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